Roquette seals Itacel deal, reinforces focus on pharma excipients

FRANCE – Roquette, a global leader in innovative plant-based ingredients, has successfully finalised its acquisition process of Itacel from Blanver.

Itacel is a leading player in the pharmaceutical excipients market in Brazil and Latin America.

Their acquisition by the Roquette will improve it as a major supplier in natural-based pharmaceutical solutions.

This joining of forces of the two businesses will also majorly improve Roquette’s strategic growth plan in the Food, Nutrition and Health markets.

This will eventually create employment opportunities to both Roquette and Itacel employees and customers.

ADVERT

Jean-Marc Gilson, CEO of Roquette, said, “This acquisition is a key milestone in the development of our service offering in the pharmaceutical industry and the expansion of our footprint in fast-growing emerging markets.

Blanver’s leadership in excipient products in Brazil and Latin America represents a significant addition to our innovation capabilities, our manufacturing assets and our commercial network.

As such, this acquisition will fully enable Roquette to continue addressing our clients’ needs worldwide.

We have been impressed by the talent of Itacel employees and are thrilled to welcome them into the Roquette family, and look forward to starting to work together.” 

Sérgio Frangioni, CEO of Blanver, added, “We believe this is the best moment to do this negotiation, mainly because we decided to focus our expansion in the two other divisions of the group that became very important for us: medicines and APIs.

ADVERT

On the other hand, Roquette has a similar culture to ours and is the best company to continue the work we began 35 years ago, when my father founded our company.”

September 1, 2017.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.